Measures of benefit for breast screening from the pathology database for Scotland, 1991-2001

Journal of Clinical Pathology

Volumn 56, Issue 9, 2003, Pages 654-659

  Anderson, T J ^a,b   Davis, C ^c   Alexander, F E ^b   Dobson, H M ^d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c INFORMATION SERVICES DIVISION   (United Kingdom)

^d Breast Screening Clinic   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER INCIDENCE; CANCER SCREENING; CANCER SIZE; DATA BASE; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PATHOLOGY; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; SCOTLAND; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 0042261956     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.9.654     Document Type: Article

References (27)

1. Tabar L, Fagerberg G, Chen HH, et al. Tumour development, histology and grade of breast cancers: prognosis and progression. Int J Cancer 1996;66:413-19.
2. Cowan WK, Angus B, Gray JC, et al. A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 2000;53:140-6.
3. McCann J, Britton PD, Warren RML, et al. Radiological peer review of interval cancers in the East Anglian breast screening programme: what are we missing? J Med Screen 2001;8:77-85.
4. Sloane J, Anderson T, Brown C, et al. Pathology reporting in breast cancer screening. Oxford: NHSBSP Publications, 1990.
5. Sloane J, Anderson T, Davies J, et al. Pathology reporting in breast cancer screening, 2nd edition. Sheffield: NHSBSP Publications, 1995.
6. Warner J, Beattie C, Sharp L, on behalf of the Scottish Breast Screening Programme Central Coordinating Team. Scottish breast screening programme report, 1993. Edinburgh: Scottish Office, Information Services Division, 1993.
7. Everington D, Gilbert FJ, Tyack C, et al. The Scottish breast screening programme's experience of monitoring interval cancers. J Med Screen 1999;6:21-7.
8. Tabar L, Duffy S, Vitak B, et al. The natural history of breast carcinoma - what have we learned from screening? Cancer 1999;86:449-62.
9. Hakama M, Holli K, Isola J, et al. Aggressiveness of screen-detected breast cancers. Lancet 1995;345:221-4.
10. Johnson A, Shekhdar J. Does breast cancer grade worsen with time? Evidence from breast screening. Breast Cancer Res Treat 2001;68:261-71.
11. Roylance R, Gorman P, Harris W, et al. Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999;59:1433-6.
12. Roylance R, Gorman P, Hanby A, et al. Allelic imbalance analysis of chromosome 16q shows that grade I and grade III invasive ductal breast cancers follow different genetic pathways. J Pathol 2002;196:32-6.
13. Alexander FE, Anderson TJ, Hubbard AL. Screening status in relation to biological and chronological characteristics of breast cancer: a cross sectional survey. J Med Screen 1997;4:152-7.
14. Anderson TJ, Alexander FE, Forrest PM. The natural history of breast carcinoma - what have we learned from screening? Cancer 2000;88:1758-9.
15. Anderson TJ, Alexander FE, Lamb J, et al. Pathology characteristics that optimize outcome prediction of a breast screening trial. Br J Cancer 2000;83:487-92.
16. Buerger H, Mommers EC, Littmann R, et al. Ductal invasive G2 and G3 carcinomas of the breast are the end stage of at least two different lines of genetic evolution. J Pathol 2001;194:165-70.
17. Cserni G. Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma. J Clin Pathol 2002;55:293-7.
18. Walter SD, Day NE. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 1983;118:865-86.
19. Tubiana M, Koscielny S. Natural-history of human breast-cancer - recent data and clinical implications. Breast Cancer Res Treat 1991;18:125-40.
20. Shapiro S, Coleman EA, Broeders M, et al. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. Int J Epidemiol 1998;27:735-42.
21. Cole P, Morrison A. Basic issues in population screening for cancer. J Natl Cancer Inst 1980;64:1263-72.
22. Blanks RG, Moss SM. Breast cancer screening sensitivity in the NHSBSP: recent results and implications. Breast 1999;8:301-2.
23. Sloane J, Ellman R, Anderson T, et al. Consistency of histopathology reporting of breast-lesions detected by screening - findings of the UK National External Quality Assessment (EQA) scheme. Eur J Cancer 1994;30A:1414-19.
24. Anderson TJ, Sufi F, Ellis IO, et al. Implications of pathologist concordance for breast cancer assessments in mammography screening from age 40 years. Hum Pathol 2002;33:365-71.
25. Day NE, Williams DRR, Khaw KT. Breast-cancer screening programs - the development of a monitoring and evaluation system. Br J Cancer 1989;59:954-8.
26. Blanks R, Day NE, Moss SM. Monitoring the performance of breast screening programs: use of indirect standardisation in evaluating the invasive cancer detection rate. J Med Screen 1996;3:79-81.
27. Evans AJ, Pinder SE, Burrell HC, et al. Detecting which invasive cancers at mammographic screening saves lives? J Med Screen 2001;8:86-90.